GIBSON DUNN

Gibson Dunn Advises Natera on Acquisition of Foresight Diagnostics

Firm News | December 5, 2025

Gibson Dunn advised Natera, Inc., a global leader in cell-free DNA and precision medicine, on its acquisition of Foresight Diagnostics, a leader in ultrasensitive molecular residual disease detection. Our corporate team included partners Branden Berns, Gina Hancock, and Jin Hee Kim.

Related People

Branden C. Berns

Gina Hancock

Jin Hee Kim

Related Capabilities

Mergers and Acquisitions

Life Sciences

© 2026 Gibson, Dunn & Crutcher LLP. All rights reserved. For contact and other information, please visit us at www.gibsondunn.com. | **www.gibsondunn.com**